Baird analyst Brian Skorney came out to defend Axovant Sciences (NYSE: AXON), which was weaker on Lilly's solanezumab failure ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA Trader Talk

Axovant Sciences (AXON), vTv Therapeutics (VTVT) Mechanisms Don't Overlap with Sola - PiperNovember 23, 2016 11:22 AM Pre-Open Stock Movers 11/23: (MDGS) (VEEV) (BLXT) Higher; (JUNO) (LLY) (URBN) Lower (more...)November 23, 2016 9:24 AM Axovant Sciences (AXON) Sinks 17% on Eli Lilly Sola FailureNovember 23, 2016 7:50 AM Dow, S&P 500 set record high closes ahead of holidayNovember 23, 2016 7:33 AM Axovant Sciences (AXON): Allergan Acquisition of Chase a Positive - BairdNovember 23, 2016 6:36 AM